Triple agonism is studied because the three receptors pull different levers: GLP-1 signalling is tied to satiety and glucose-dependent insulin release, GIP to insulin response and adipose signalling, and glucagon to energy expenditure. A molecule that engages all three lets researchers ask what the combination does that no single signal can — and which receptor contributes what.
In practice, labs use GLP-3R in receptor-activation assays, comparative pharmacology against single and dual agonists, and preclinical models of appetite, glucose regulation and energy balance. Because the class is so young, much of the published work is head-to-head profiling — exactly the kind of study a well-characterized reference vial supports.